PE20161406A1 - Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas - Google Patents
Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estasInfo
- Publication number
- PE20161406A1 PE20161406A1 PE2016001528A PE2016001528A PE20161406A1 PE 20161406 A1 PE20161406 A1 PE 20161406A1 PE 2016001528 A PE2016001528 A PE 2016001528A PE 2016001528 A PE2016001528 A PE 2016001528A PE 20161406 A1 PE20161406 A1 PE 20161406A1
- Authority
- PE
- Peru
- Prior art keywords
- tatk
- formulations
- compositions
- seq
- fusion proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4737—C-reactive protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946280P | 2014-02-28 | 2014-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161406A1 true PE20161406A1 (es) | 2017-01-14 |
Family
ID=53539745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001528A PE20161406A1 (es) | 2014-02-28 | 2015-02-27 | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas |
Country Status (33)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055282T2 (hu) * | 2014-02-28 | 2021-11-29 | Univ Bologna Alma Mater Studiorum | TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása |
| US20210268072A1 (en) * | 2016-06-28 | 2021-09-02 | Alma Mater Studiorum - Universitá Di Bologna | TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof |
| CN111936624A (zh) * | 2017-11-30 | 2020-11-13 | 阿米库斯治疗学公司 | Cdkl5表达变体和cdkl5融合蛋白 |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| WO2021087282A1 (en) * | 2019-10-30 | 2021-05-06 | Amicus Therapeutics, Inc. | Recombinant cdkl5 proteins, gene therapy and production methods |
| AU2021218703A1 (en) | 2020-02-14 | 2022-07-28 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating CDKL5 deficiency disorder |
| IT202000025423A1 (it) * | 2020-10-27 | 2022-04-27 | Ulisse Biomed S P A | Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali |
| WO2022119890A1 (en) | 2020-12-01 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| CA3229127A1 (en) * | 2021-08-18 | 2023-02-23 | Julie Yu Wei | Recombinant aav formulations |
| CN116874571A (zh) * | 2021-12-17 | 2023-10-13 | 博格隆(上海)生物技术有限公司 | 突变的蛋白a结构域c及其应用 |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ609640A (en) * | 2010-10-25 | 2015-06-26 | Univ D’Aix Marseille | Treatment of mecp2-associated disorders |
| HUE055282T2 (hu) * | 2014-02-28 | 2021-11-29 | Univ Bologna Alma Mater Studiorum | TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása |
-
2015
- 2015-02-27 HU HUE19179287A patent/HUE055282T2/hu unknown
- 2015-02-27 CR CR20160392A patent/CR20160392A/es unknown
- 2015-02-27 LT LTEP15736034.8T patent/LT3110837T/lt unknown
- 2015-02-27 JP JP2016553630A patent/JP6629747B2/ja active Active
- 2015-02-27 PT PT15736034T patent/PT3110837T/pt unknown
- 2015-02-27 PE PE2016001528A patent/PE20161406A1/es not_active Application Discontinuation
- 2015-02-27 SI SI201531680T patent/SI3608334T1/sl unknown
- 2015-02-27 SM SM20210478T patent/SMT202100478T1/it unknown
- 2015-02-27 EP EP15736034.8A patent/EP3110837B1/en active Active
- 2015-02-27 EP EP19179287.8A patent/EP3608334B1/en active Active
- 2015-02-27 PL PL15736034T patent/PL3110837T3/pl unknown
- 2015-02-27 DK DK15736034.8T patent/DK3110837T3/da active
- 2015-02-27 CA CA2940401A patent/CA2940401C/en active Active
- 2015-02-27 RS RS20211041A patent/RS62244B1/sr unknown
- 2015-02-27 CN CN201580010858.9A patent/CN106255706A/zh active Pending
- 2015-02-27 DK DK19179287.8T patent/DK3608334T3/da active
- 2015-02-27 SM SM20190504T patent/SMT201900504T1/it unknown
- 2015-02-27 RS RSP20191144 patent/RS59344B1/sr unknown
- 2015-02-27 MX MX2020001223A patent/MX392778B/es unknown
- 2015-02-27 MX MX2016011167A patent/MX2016011167A/es active IP Right Grant
- 2015-02-27 ES ES15736034T patent/ES2745335T3/es active Active
- 2015-02-27 US US14/633,757 patent/US9290746B2/en active Active
- 2015-02-27 MY MYPI2016001567A patent/MY181566A/en unknown
- 2015-02-27 WO PCT/IB2015/000999 patent/WO2015128746A2/en not_active Ceased
- 2015-02-27 ES ES19179287T patent/ES2885245T3/es active Active
- 2015-02-27 PT PT191792878T patent/PT3608334T/pt unknown
- 2015-02-27 HU HUE15736034A patent/HUE045393T2/hu unknown
- 2015-02-27 SG SG10202000537RA patent/SG10202000537RA/en unknown
- 2015-02-27 LT LTEP19179287.8T patent/LT3608334T/lt unknown
- 2015-02-27 EA EA201691691A patent/EA038000B1/ru unknown
- 2015-02-27 SG SG11201606863YA patent/SG11201606863YA/en unknown
- 2015-02-27 EA EA202190727A patent/EA202190727A3/ru unknown
- 2015-02-27 HR HRP20191511 patent/HRP20191511T1/hr unknown
- 2015-02-27 BR BR112016019868-9A patent/BR112016019868B1/pt not_active IP Right Cessation
- 2015-02-27 AU AU2015221860A patent/AU2015221860B2/en active Active
- 2015-02-27 SI SI201530884T patent/SI3110837T1/sl unknown
- 2015-02-27 KR KR1020167026521A patent/KR102307276B1/ko not_active Expired - Fee Related
- 2015-02-27 PL PL19179287T patent/PL3608334T3/pl unknown
-
2016
- 2016-03-21 US US15/075,457 patent/US9944910B2/en active Active
- 2016-08-23 DO DO2016000220A patent/DOP2016000220A/es unknown
- 2016-08-24 CL CL2016002142A patent/CL2016002142A1/es unknown
- 2016-08-25 IL IL247481A patent/IL247481B/en active IP Right Grant
- 2016-08-25 PH PH12016501689A patent/PH12016501689A1/en unknown
- 2016-08-26 SV SV2016005264A patent/SV2016005264A/es unknown
- 2016-08-26 NI NI201600127A patent/NI201600127A/es unknown
- 2016-09-26 ZA ZA2016/06655A patent/ZA201606655B/en unknown
-
2018
- 2018-04-16 US US15/954,021 patent/US10584318B2/en active Active
-
2019
- 2019-08-20 AU AU2019219743A patent/AU2019219743B2/en active Active
- 2019-09-11 CY CY20191100949T patent/CY1122644T1/el unknown
- 2019-09-25 ZA ZA2019/06304A patent/ZA201906304B/en unknown
- 2019-12-05 JP JP2019220178A patent/JP6896050B2/ja active Active
-
2020
- 2020-03-06 US US16/811,484 patent/US10907138B2/en active Active
- 2020-06-17 IL IL275435A patent/IL275435B/en unknown
-
2021
- 2021-08-17 HR HRP20211324TT patent/HRP20211324T1/hr unknown
- 2021-08-19 CY CY20211100743T patent/CY1124727T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40283A (es) | Método para alterar una propiedad de una planta | |
| MX389878B (es) | Proteinas quimericas de factor viii y usos de estas. | |
| MX392683B (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| MX2017006866A (es) | Pares de unión para producción de péptidos. | |
| MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
| CO2017002166A2 (es) | Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa | |
| MX2018005063A (es) | Polipéptidos condicionalmente activos. | |
| PH12018502361B1 (en) | Gdf15 fusion proteins and uses thereof | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| CL2016001405A1 (es) | A peptide mixture | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| MX2020001223A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. | |
| WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
| MX2018013331A (es) | Vector de vacuna de levadura que incluye polipeptidos inmunoestimuladores y antigenicos y metodos para su uso. | |
| MY195945A (en) | Ras Protein Degradation Inducing Molecule and Pharmaceutical Composition | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| MX2019002248A (es) | Proteina de union al factor h modificada. | |
| EA201891747A1 (ru) | Полинуклеотиды и полипептиды slam и их использование | |
| UY36616A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
| PE20180162A1 (es) | Polipeptidos dirigidos a la fusion de vih | |
| MX374380B (es) | Composicion inmunógena de clostridium difficile. | |
| AR122764A2 (es) | Formulación de un polipéptido del factor viii, kit farmacéutico, método |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |